Skip to Accessibility Tools Skip to Content Skip to Footer

AbbVie Announces Viekira Pak Achieves 100% SVR

On June 24, AbbVie announced, in a recent trial, its chronic hepatitis C (HCV) Viekira Pak taken without Ribavirin achieved a sustained virologic response (SVR) in 12 weeks for 100% of patients with genotype 1b and compensated liver cirrhosis. The treatment is an oral combination of Viekirax and Exviera. Ribavirin is an older treatment sometimes used in tandem other treatments.1,2

After treatment ended, no patients reported a virologic relapse. Some common side effects experienced from the treatment included fatigue, diarrhea, and headaches.1

Genotype 1 is the most common for hepatitis C and accounts for approximately 60% of the 160 million HCV patients worldwide.2

This new data emerges after the Food & Drug Administration (FDA) approved Viekira Pak back in December after the treatment showed a 91-100% SVR. The combination treatment was approved in Europe in January and approved in Canada under the named Holkira Pak in December.1

For more information on the treatment or its prescription assistance program, visit AbbVie’s Viekira Pak website.